Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of CHF 5074 in Mild Cognitive Impairment
NCT01421056Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jul 2011
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Itanapraced in Mild Cognitive Impairment (MCI) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Maximum Tolerated Dose at 24 weeks. Started Jul 2011; status: completed.
02
Drugs
Itanapraced
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT01421056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01421056.